Evidence map›Paper›PMID 34651103›Full record

ArticleHemaSphere2021

Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance.

Stephen Boyle, Joshua W D Tobin, Jacinta Perram, Nada Hamad, Veena Gullapalli, Allison Barraclough, Lydia Singaraveloo, Min-Hi Han, Richard Blennerhassett, Niles Nelson and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. BaselineHemaSphere · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 14 institutions in 1 country.

Stephen BoyleDepartment of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Joshua W D TobinUniversity of Queensland, Brisbane, Queensland, Australia.
Jacinta PerramInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Nada HamadDepartment of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
Veena GullapalliDepartment of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
Allison BarracloughDepartment of Haematology and Olivia Newton John Cancer Research Institute, The Austin Hospital, Melbourne, Victoria, Australia.
Lydia SingaravelooRoyal Adelaide Hospital, Adelaide, South Australia, Australia.
Min-Hi HanDepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Richard BlennerhassettDepartment of Haematology, Westmead Hospital, Sydney, New South Wales, Australia.
Niles NelsonRoyal Hobart Hospital, Hobart, Tasmania, Australia.
Anna M JohnstonRoyal Hobart Hospital, Hobart, Tasmania, Australia.
Dipti TalaulikarDepartment of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Krishna KarpeDepartment of Renal Medicine, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Abir BhattacharyyaDepartment of Haematology, Westmead Hospital, Sydney, New South Wales, Australia.
Chan Yoon CheahDepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Elango SubramoniapillaiRoyal Brisbane Hospital, Brisbane, Queensland, Australia.
Waqas BokhariRoyal Brisbane Hospital, Brisbane, Queensland, Australia.
Cindy LeeRoyal Adelaide Hospital, Adelaide, South Australia, Australia.
Eliza A HawkesDepartment of Haematology and Olivia Newton John Cancer Research Institute, The Austin Hospital, Melbourne, Victoria, Australia.
Andrew JabbourDepartment of Cardiology, St Vincent's Hospital, Sydney, New South Wales, Australia.
Simone I StrasserUniversity of Sydney, Sydney, New South Wales, Australia.
Steven J ChadbanUniversity of Sydney, Sydney, New South Wales, Australia.
Christina BrownInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Peter MolleeDepartment of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Greg HapgoodDepartment of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
The University of Sydney · AUPrincess Alexandra Hospital · AUSt Vincent's Hospital Sydney · AURoyal Adelaide Hospital · AURoyal Brisbane and Women's Hospital · AURoyal Hobart Hospital · AUSir Charles Gairdner Hospital · AUAustin Hospital · AUAustralian National University · AUCanberra Hospital · AUGold Coast Hospital · AURoyal Prince Alfred Hospital · AUThe University of Melbourne · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are limited data on post-transplant lymphoproliferative disorder (PTLD) in the era of positron emission tomography (PET) and rituximab (R). Furthermore, there is limited data on the risk of graft rejection with modern practices in reduction in immunosuppression (RIS). We studied 91 patients with monomorphic diffuse large B-cell lymphoma PTLD at 11 Australian centers: median age 52 years, diagnosed between 2004 and 2017, median follow-up 4.7 years (range, 0.5-14.5 y). RIS occurred in 88% of patients. For patients initially treated with R-monotherapy, 45% achieved complete remission, rising to 71% with the addition of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) for those not in complete remission. For patients initially treated with R-CHOP, the complete remission rate was 76%. There was no difference in overall survival (OS) between R-monotherapy and R-chemotherapy patients. There was no difference in OS for patients with systemic lymphoma (n = 68) versus central nervous system (CNS) involvement (n = 23) (3-y OS 72% versus 73%;

Identifiers

PMID34651103
PMCPMC8505336
OpenAlexW3207947031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.